Your browser doesn't support javascript.
Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic.
Dumitrescu, L; Papathanasiou, A; Coclitu, C; Constantinescu, C S; Popescu, B O; Tanasescu, R.
  • Dumitrescu L; From the Department of Clinical Neurosciences, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania.
  • Papathanasiou A; Department of Neurology, Colentina Hospital, Bucharest, Romania.
  • Coclitu C; Department of Neurology, Queen's Medical Centre, Nottingham University Hospitals, Nottingham, UK.
  • Constantinescu CS; Department of Multiple Sclerosis and Neuroimmunology, CHU Grenoble, Grenoble, France.
  • Popescu BO; Department of Neurology, Queen's Medical Centre, Nottingham University Hospitals, Nottingham, UK.
  • Tanasescu R; Academic Clinical Neurology, Division of Clinical Neuroscience, C Floor, South Block, Queen's Medical Centre, Derby Road, NG7 2UH, Nottingham, UK.
QJM ; 114(10): 691-697, 2021 Dec 20.
Article in English | MEDLINE | ID: covidwho-1041817
ABSTRACT
Beta interferons (IFN-ß) are pleiotropic cytokines with antiviral properties. They play important roles in the pathogenesis of multiple sclerosis (MS), an incurable immune-mediated disorder of the central nervous system. The clinical expression of MS is heterogeneous, with relapses of neuroinflammation and with disability accrual in considerable part unrelated to the attacks. The injectable recombinant IFN-ß preparations are the first approved disease-modifying treatments for MS. They have moderate efficacy in reducing the frequency of relapses, but good long-term cost-efficacy and safety profiles, so are still widely used. They have some tolerability and adherence issues, partly mitigated in recent years by the introduction of a PEGylated formulation and use of 'smart' autoinjector devices. Their general impact on long-term disability is modest but could be further improved by developing accurate tools for identifying the patient profile of best responders to IFN-ß. Here, we present the IFN-ß-based immunomodulatory therapeutic approaches in MS, highlighting their place in the current coronavirus disease (COVID-19) pandemic. The potential role of IFN-ß in the treatment of COVID-19 is also briefly discussed.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interferon-beta / COVID-19 Drug Treatment / Immunotherapy / Multiple Sclerosis Type of study: Prognostic study Limits: Humans Language: English Journal: QJM Journal subject: Medicine Year: 2021 Document Type: Article Affiliation country: Qjmed

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Interferon-beta / COVID-19 Drug Treatment / Immunotherapy / Multiple Sclerosis Type of study: Prognostic study Limits: Humans Language: English Journal: QJM Journal subject: Medicine Year: 2021 Document Type: Article Affiliation country: Qjmed